Cubist Systematic Strategies’s Recursion Pharmaceuticals RXRX Stock Holding History

Cubist Systematic Strategies’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-30,920	Closed	-$308K	–	3869
2024 Q1	$308K	Buy	30,920 +17,816	+136%	+$198K	﹤0.01%	2860
2023 Q4	$129K	Buy	+13,104	New	+$93.4K	﹤0.01%	3123
2023 Q2	–	Sell	-406,662	Closed	-$2.71M	–	4196
2023 Q1	$2.71M	Buy	406,662 +246,829	+154%	+$1.96M	0.02%	1422
2022 Q4	$1.23M	Buy	159,833 +48,258	+43%	+$473K	0.01%	2258
2022 Q3	$1.19M	Buy	111,575 +88,167	+377%	+$893K	0.01%	2478
2022 Q2	$191K	Sell	23,408 -65,340	-74%	-$437K	﹤0.01%	3730
2022 Q1	$635K	Buy	88,748 +54,971	+163%	+$584K	0.01%	2382
2021 Q4	$579K	Buy	33,777 +6,091	+22%	+$115K	0.01%	2338
2021 Q3	$637K	Buy	27,686 +14,086	+104%	+$399K	0.01%	1858
2021 Q2	$496K	Buy	+13,600	New	+$403K	0.01%	2016

Other funds holding RXRX

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

MIC

Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cubist Systematic Strategies's RXRX Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of Recursion Pharmaceuticals (RXRX) in Q2 2024, closing a stake of 30,920 shares — an estimated $308K sold.

Cubist Systematic Strategies first reported a position in RXRX in Q2 2021 and held it in 10 quarters. The position peaked at $2.71M in Q1 2023. 270 funds tracked by Wall St. Rank hold RXRX as of Q2 2024.

Cubist Systematic Strategies reported no remaining Recursion Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Cubist Systematic Strategies sold 30,920 Recursion Pharmaceuticals shares in Q2 2024, an estimated $308K.
Cubist Systematic Strategies first reported a position in Recursion Pharmaceuticals in Q2 2021 and held it in 10 quarters.
Cubist Systematic Strategies's Recursion Pharmaceuticals position peaked at $2.71M in Q1 2023.
270 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.